EP2007312A2 - Approche basée sur la forme pour ingéniérie tissulaire sans échafaudage - Google Patents
Approche basée sur la forme pour ingéniérie tissulaire sans échafaudageInfo
- Publication number
- EP2007312A2 EP2007312A2 EP07760209A EP07760209A EP2007312A2 EP 2007312 A2 EP2007312 A2 EP 2007312A2 EP 07760209 A EP07760209 A EP 07760209A EP 07760209 A EP07760209 A EP 07760209A EP 2007312 A2 EP2007312 A2 EP 2007312A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- constructs
- construct
- hydrogel
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/76—Agarose, agar-agar
Definitions
- Tissue engineering is an area of intense effort today in the field of biomedical sciences.
- the development of methods of tissue engineering and replacement is of particular importance in tissues that are unable to heal or repair themselves, such as tissues of the knee meniscus.
- the meniscus is a load bearing, fibrocartilaginous tissue within the knee joint that is responsible for lubrication, stability, and shock absorption.
- Regions of the meniscus namely those in the avascular zone, are virtually incapable of healing or repairing themselves adequately in response to trauma or pathology. Loss of mechanical function of the meniscus is associated with development of degeneration and eventual osteoarthritis.
- fibrocartilaginous tissue regeneration strategies have been scaffold-based.
- Many synthetic polymers can induce inflammatory responses or create a local environment unfavorable to the biologic activity of cells.
- the major problem associated with natural polymer scaffolds is reproducibility.
- these methods typically involve seeding cultured fibrochondrocytes into a biological or synthetic scaffold. The seeded cells may migrate from the scaffold to the bottom of the culture vessel or well, even if the plates are not treated to promote cell adhesion. Cells plated on non-tissue-treated plates may still eventually attach.
- proteins made by the cells or supplied in the medium have usually adsorbed onto the bottom of the wells to promote attachment. This results in a reduction in the size of the construct.
- Another drawback is that the attached cells tend to flatten and change to a different phenotype. Those cells compete with the remaining fibrochondrocytes for nutrients and do not produce the desired extracellular matrix proteins for tissue regeneration.
- Figure 3 shows the total ECM per construct in micrograms. Data are shown as mean ⁇ standard deviation, and significance is defined as p ⁇ 0.05. Significant groups are separated by different letters. Constructs cultured over agarose contained significantly more ECM per construct than constructs cultured on TCP at the same time points. A) Total GAG per construct. Significant increases in GAG per construct were observed for both treatments. B) Total collagen per construct. Significant increases in collagen per construct were observed for both treatments. Due to the absence of immunohistochemistry staining for collagen type I, and also due to gel electrophoresis, most of the collagen produced is considered type II.
- HA aggregate modulus
- Figure 5 shows the pressure chamber assembly consisting of a 1.2 L stainless-steel vessel (A) connected to a water-driven piston (B) seated on an Instron 8871 (C). Cells were placed in heat-sealed bags and placed in the stainless-steel vessel (A). The vessel was then placed in an adjacent water bath (not shown). The Instron (C) drove the piston (B) to pressurize the fluid within.
- A 1.2 L stainless-steel vessel
- B water-driven piston
- C Instron 8871
- Figure 10 shows the meniscal shaped hydrogel with media and the construct being cultured in the bottom of the culture vessel.
- Figure 11 shows the meniscal shaped press used to shape the molten hydrogel in the culture vessel.
- Figure 12 shows the gross morphology of the tissue engineered constructs. Percentages given refer to the articular chondrocyte content of the culture.
- Figure 13 shows a cross-sectional view of the tissue engineered construct developed using a culture of 50% articular chondrocytes and 50% meniscal fibrochondrocytes. Red dye has been added to the image for ease of visualizing the cross section.
- Figure 14 is a graph of the wet weight of the constructs relative to the percentage of articular chondrocytes in the culture.
- Figure 15 is a graph of the percentage of water in the constructs as compared to the percentage of articular chondrocytes in the culture
- Figure 16 is a graph of the tensile modulus of the constructs as compared to the percentage of articular chondrocytes in the culture.
- Figure 17 is a graph of the ultimate tensile strength of the constructs as compared to the percentage of articular chondrocytes in the culture.
- Figure 18 is a graph of the aggregate modulus of the constructs as compared to the percentage of articular chondrocytes in the culture.
- Figure 19 is a graph of the cell number per milligram of tissue dry weight of the constructs as compared to the percentage of articular chondrocytes in the culture.
- Figure 20 is a graph of percentage of glycosaminoglycans by dry weight of the constructs as compared to the percentage of articular chondrocytes in the culture.
- Figure 21 is a graph of percentage of collagen by dry weight of the constructs as compared to the percentage of articular chondrocytes in the culture.
- Figure 22 (A) shows a fabricated cartilage well and a tissue engineered construct press-fit into the well. This approach will be used to create an in vitro model of integration.
- Figure 22 (B) shows a 50:50 co-culture made in the shape of the knee meniscus. Each hash mark is 0.5 cm.
- Figure 23 shows a negative mold comprised of agarose.
- Figure 24 shows a positive mold comprised of agarose.
- the agarose is saturated with culture medium, resulting in the reddish shade.
- Figure 25 shows various views of scaffoldless femur constructs made by the methods of the present disclosure.
- Figure 26 shows a comparison of the tissue engineered femur construct to a femur shaped piece of plastic. In this case, the construct was formed to resurface only part of, as opposed to the entire, femur.
- tissue engineered constructs without the use of scaffolds and associated methods of use in tissue replacement.
- a "construct" or “tissue engineered construct” refers to a three-dimensional mass having length, width, and thickness, and which comprises living mammalian tissue produced in vitro.
- the methods of this disclosure generally comprise the formation of a tissue engineered constructs without the use of scaffolds or other synthetic materials. Generally, cells are seeded on a shaped hydrogel mold and allowed to self-assemble to form a construct.
- self-assemble or “self-assembly” refers to a process in which specific local interactions and constraints between a set of components cause the components to autonomously assemble, without external assistance, into the final desired structure through exploration of alternative configurations.
- the methods of the present disclosure provide for higher cell-cell contact. Chondrocytes are unique in their need to remain in a spherical morphology to maintain their phenotype. Since the chondrocytes' only substrate for attachment is other chondrocytes in the methods of the present disclosure, this may enhance the cell to cell signaling necessary to maintain the chondrocytic phenotype.
- Another advantage of the methods of the present disclosure is that biocompatibility issues of the scaffold and its degradation materials are avoided as well as stress-shielding of the seeded cells by the scaffold. Cell reaction to the biomaterial, such as dedifferentiation, is also avoided. Furthermore, because stress shielding by the scaffold does not occur, the methods of the present disclosure may allow for the cells to respond directly to forces which may aid in aligning extracellular matrix production. Another advantageous feature of the present disclosure is that it allows manipulation of the thickness, geometry, and size of the resulting construct.
- hydrogel used in conjunction with the methods of the present disclosure may comprise agarose, alignate, or combinations thereof.
- a "hydrogel” is a colloid in which the particles are in the external or dispersion phase and water is in the internal or dispersed phase. Suitable hydrogels are nontoxic to the cells, are non-adhesive, do not induce chondrocytic attachment, allow for the diffusion of nutrients, do not degrade significantly during culture, and are firm enough to be handled.
- the hydrogel used in conjunction with the present disclosure is melted to form a molten hydrogel.
- the molten hydrogel is introduced into a culture vessel and may be shaped using a shaped press.
- the press may be shaped to accommodate the desired shape of the tissue engineered construct.
- the press may be in the shape of a ring.
- the press may be a projection of the medial meniscus rotated through 360 degrees.
- the resulting pressed molten hydrogel is allowed to cool around the shape of the press.
- a cooled shaped hydrogel negative mold is left remaining in the culture vessel.
- the shape of the resulting pressed hydrogel is a projection of the medial meniscus rotated through 360 degrees, hi certain embodiments, a ring shape of the shaped hydrogel negative mold may aid in the alignment of the extracellular matrix during the formation of the tissue engineered construct by subjecting the developing construct to a hoop strain during cell culture.
- the cells used in conjunction with the methods of the present disclosure may be chondrocytes, fibrochondrocytes, or combinations thereof.
- the chondrocytes may comprise articular chondrocytes.
- the articular chondrocytes may be from a bovine or porcine source.
- the source of articular chondrocytes may be autologous cartilage from a small biopsy of the patient's own tissue, provided that the patient has healthy articular cartilage that may be used as the start of in vitro expansion.
- Another suitable source of chondrocytes is heterologous chondrocytes from histocompatible cartilage tissue obtained from a donor or cell line.
- the fibrochondrocytes used in conjunction with the methods of the present disclosure may comprise meniscal fibrochondrocytes.
- the meniscal fibrochondrocytes may be from a bovine or porcine source for in vitro studies.
- the source of meniscal fibrochondrocytes may be autologous fibrocartilage from a small biopsy of the patient's own tissue, provided that the patient has healthy meniscal fibrocartilage that may be used as the start of in vitro expansion.
- Another suitable source of fibrochondrocytes is heterologous fibrochondrocytes from histocompatible fibrocartilaginous tissue obtained from a donor or cell line.
- the chondrocytes and fibrochondrocytes used in conjunction with the methods of the present disclosure may be derived from mesenchymal or skin cells.
- fibrochondrocytes, chondrocytes, or a co-culture of the two are suspended in media.
- suitable media may be DMEM with 4.5 g/L-glucose and L- glutamine(Biowhittaker), 10% fetal bovine serum (Biowhittaker), 1% fungizone (Biowhittaker), 1 % Penicillin/ Streptomycin (Biowhittaker), 1% non-essential amino acids (Life Technologies), 0.4 mM proline (ACS Chemicals), 10 mM HEPES (Fisher Scientific), 50 ⁇ g/mL L-ascorbic acid, (Acros Organics) supplemented with 20% FBS and 10% DMSO.
- the cells may comprise 50% fibrochondrocytes and 50% chondrocytes.
- the cells may be seeded in a shaped hydrogel negative mold or a hydrogel coated culture vessel and allowed to self-assemble.
- the cells may be seeded at a density in the range of about 10 x 10 6 cells per cm 2 to 9O x 10 6 cells per cm 2 of hydrogel coated surface.
- the suspension of f ⁇ brochondrocytes and chondrocytes is seeded at a density of 24 x 10 6 cells/ cm 2 of hydrogel coated surface.
- the cells may be seeded at a density of about 29 x 10 6 cells/ cm 2 of hydrogel coated surface.
- the cells seeded on hydrogel coated culture vessels or hydrogel negative molds are allowed to self-assemble.
- Self-assembly may result in the formation of non-attached constructs on the hydrogel surfaces. It is preferable to use hydrogel coated surfaces instead of tissue culture treated surfaces since articular chondrocytes seeded onto standard tissue culture treated plastic (TCP) readily attach, spread, and dedifferentiate.
- TCP tissue culture treated plastic
- the self-assembly process may occur in culture vessels that are shaken continuously on an orbital shaker and then pressurized, hi certain embodiments, the pressurization of the cells may occur in a pressure chamber. Pressurization of the samples during the self-assembly process may aid in increased extracellular matrix synthesis and enhanced mechanical properties.
- the cells may be pressurized to 10 MPa at IHz using a sinusoidal waveform function.
- the cells are pressurized during culture of the self- assembled cells.
- a loading regimen e.g. compressive, tensile, shear forces
- Loading of the cells during self-assembly and/or construct development may cause enhanced gene expression and protein expression in the constructs.
- the cells may be treated with staurosporine, a protein kinase C inhibitor and actin disrupting agent, during the self-assembly process to reduce synthesis of ⁇ SMA, a contractile protein. Reducing ⁇ SMA in the constructs via staurosporine treatment may reduce construct contraction and may also upregulate ECM synthesis.
- the cells may be treated with growth factors to increase construct growth and matrix synthesis.
- growth factors that may be used with the methods of the present disclosure include, but are not limited to, TGF- ⁇ l and IGF-I.
- the dosing of the growth factors may be intermittent or continuous throughout the period of the self-assembly process.
- One of ordinary skill in the art, with the benefit of this disclosure, will be able to determine the appropriate dosing regimen and amount and type of growth factor to provide to the developing constructs. Hydro gel Molds
- the cells used in conjunction with the methods of the present disclosure may be seeded on a hydrogel coated culture vessel and allowed to self-assemble for about 1 to about 7 days before being transferred to a shaped hydrogel negative mold.
- the cells may be seeded directly onto a shaped hydrogel negative mold.
- the shaped hydrogel negative mold may comprise agarose.
- Other non-adhesive hydrogels e.g.
- the hydrogel mold may be a two piece structure comprising, a shaped hydrogel negative mold (See for example, Figure 23) and a shaped hydrogel positive mold (See for example, Figure 24).
- the shaped hydrogel negative and positive molds may comprise the same non-adhesive hydrogel or may be a comprised of different non-adhesive hydrogels.
- the cells may be seeded on a hydrogel coated culture vessel and allowed to self-assemble into a first construct. The first construct may be transferred to a shaped hydrogel negative mold.
- a shaped hydrogel positive mold may be applied to the negative mold to form a mold-construct assembly. The mold-construct assembly may then further be cultured to form a second construct.
- the term "mold-construct assembly” refers to a system comprising a construct or cells within a shaped positive and a shaped negative hydrogel mold.
- the molds may be shaped from a 3-D scanning of a total joint to result in a mold fashioned in the shape of said joint, hi other embodiments, the molds may be shaped from a 3-D scanning of the ear, nose, or other non-articular cartilage to form molds in the shapes of these cartilages. In certain embodiments, the mold may be shaped to be the same size as the final cartilaginous product. In other embodiments, the molds may be shaped to be smaller than the final cartilaginous product. In certain embodiments, the molds may be fashioned to a portion of a joint or cartilage so that it serves as a replacement for only a portion of said joint or cartilage (See Figures 25 and 26). Analysis of the Constructs
- the properties of the constructs may be tested using any number of criteria including, but not limited to, morphological, biochemical, and biomechanical properties, which also may be compared to native tissue levels.
- morphological examination includes histology using safranin-O and fast green staining for glycosaminoglycan (GAG ) content, as well as picro-sirius red staining for total collagen, immunohistochemistry for collagens I and II, and confocal and scanning electron microscopies for assessing cell-matrix interactions.
- Biochemical assessments includes picogreen for quantifying DNA content, DMMB for quantifying GAG content, hydroxyproline assay for quantifying total collagen content, and ELISA for quantifying amounts of specific collagens (I and II).
- Constructs also may be evaluated using one or more of incremental tensile stress relaxation incremental compressive stress relaxation, and biphasic creep indentation testing to obtain moduli, strengths, and viscoelastic properties of the constructs.
- Incremental compressive testing under stress relaxation conditions may be used to measure a construct' s compressive strength and stiffness.
- Incremental tensile stress relaxation testing may be used to measure a construct's tensile strength and stiffness.
- indentation testing under creep conditions may be used to measure a construct's modulus, Poisson's ratio, and permeability.
- the constructs of the present disclosure may be assessed morphologically and/or quantitatively. Quantitatively, the constructs of the present disclosure may be evaluated using a functionality index (FI) as described in Eq. 1.
- the functionality index is an equally weighted analysis of ECM production and biomechanical properties that includes quantitative results corresponding to the constructs' salient compositional characteristics (i.e., amounts of collagen II and GAG) and biomechanical properties (compressive and tensile moduli and strengths).
- G represents the GAG content per wet weight
- C represents the collagen II content per wet weight
- E ⁇ represents the tensile stiffness modulus
- E? represents the compressive stiffness modulus
- S ⁇ represents the tensile strength
- S 0 represents the compressive strength.
- Each term is weighted to give equal contribution to collagen, GAG, tension, and compression properties.
- the subscripts nat and sac are used to denote native and self-assembled construct values, respectively.
- the aggregate modulus is not used in Eq. 1, as it is expected to mirror the compressive modulus obtained from incremental compressive stress relaxation.
- the amount of collagen I is not be used in Eq. 1, as this type of collagen may not appear in a measurable fashion; however, if the amount of collagen I is non-negligible, FI may be altered accordingly to account for it.
- Each term grouped in parentheses in Eq. 1 calculates how close each construct property is with respect to native values, such that scores approaching 1 denote values close to native tissue properties. Equal weight is given to GAG, collagen II, stiffness (equally weighted between compression and tension), and strength (also equally weighted between compression and tension).
- This index, FI will be used to assess the quality of the construct compared to native tissue values, with a lower limit of 0 and an unbounded upper limit, with a value of 1 being a construct possessing properties of native tissue. However, the FI can exceed 1 if optimization results in constructs of properties superior to native tissue.
- a hydrogel coated culture vessel or shaped hydrogel negative mold is seeded with cells to produce new tissue, such as tissue of the knee meniscus, tendons, and ligaments.
- the hydrogel coated culture vessel or shaped hydrogel negative mold is typically seeded with cells; the cells are allowed to self-assemble to form a tissue engineered construct.
- applications of the tissue engineered construct include the replacement of tissues, such as the knee meniscus, joint linings, the temporomandibular joint disc, tendons, or ligaments.
- the constructs may be treated with collagenase, chondroitinase ABC, and BAPN to aid in the integration of the constructs with native, healthy cartilage surrounding the desired location of implantation.
- the integration capacity of a construct with native tissue is crucial to regeneration.
- a wound is naturally anti-adhesive, but debridement with chondroitinase ABC and/or collagenase removes anti-adhesive GAGs and enhances cell migration by removing dense collagen at the wound edge.
- BAPN a lysyl oxidase inhibitor, may cause the accumulations of matrix crosslinkers and may, thus, strengthen the interface between the construct and native tissue at the desired location of implantation.
- the tissue engineered constructs may be implanted into a subject and used to treat a subject in need of tissue replacement.
- the constructs may be grown in graded sizes (e.g. small, medium, and large) so as to provide a resource for off-the-shelf tissue replacement.
- the constructs may be formed to be of custom shape and thickness.
- the constructs may be devitalized prior to implantation into a subject.
- Example 1 Isolation and Seeding of Chondrocytes and Fibrochondrocytes
- Chondrocytes were isolated from the distal femur of week-old male calves (Research 87 Inc.) less than 36 hrs after slaughter, with collagenase type I (Worthington) in culture medium.
- the medium was DMEM with 4.5 g/L-glucose and L-glutamine(Biowhittaker), 10% fetal bovine serum (Biowhittaker), 1% fungizone (Biowhittaker), 1 % Penicillin/ Streptomycin (Biowhittaker), 1% non-essential amino acids (Life Technologies), 0.4 mM proline (ACS Chemicals), 10 mM HEPES (Fisher Scientific), and 50 ⁇ g/mL L-ascorbic acid (Acros Organics).
- Chondrocytes were frozen in culture medium supplemented with 20% FBS and 10% DMSO at -80 0 C for 2 wks to a month before cells from two donor legs were pooled together. Cells from each leg were counted on a hemocytometer, and viability was assessed using a trypan blue exclusion test. Each leg yielded roughly 150 million cells, and viability was greater than 99% for both legs. After thawing, viability remained greater than 92%.
- Fibrochondrocytes were harvested from the medial meniscus of approximately 1-wk old male calves (Research 87, Boston, MA) less than 36 hrs after slaughter, with collagenase in the culture medium.
- the medium was DMEM with 4.5 g/L-glucose and L-glutamine, 10% FBS, 1% fungizone, 1% Penicillin/Streptomycin, 1% non-essential amino acids, 0.4 mM proline, 10 mM HEPES, and 50 ⁇ g/mL L-ascorbic acid.
- Cells were frozen at -8O 0 C in culture medium supplemented with 20% FBS and 10% DMSO for 2 to 4 wks before cells from donor legs can be pooled together.
- Example 2 Formation of the Hydro gel Molds
- a silicon positive die consisting of 5 mm diameter x 10 mm long cylindrical prongs has been constructed to fit into a 6-well plate.
- sterile, molten 2% agarose will be introduced into a well fitted with the silicon positive die.
- the agarose will be allowed to gel at room temperature for 15 min.
- the agarose mold will then be separated from the silicon positive die and submerged into two exchanges of culture medium.
- the agarose mold will thus be completely saturated with the culture medium by the time of cell seeding.
- To each agarose well 5.5 x 10 6 cells will be added in 50 ⁇ l of culture medium.
- the cells will self-assemble within 24 hrs in the agarose wells and will be maintained in the same wells for 3 days.
- Example 3 Self Assembly and Culture of the Tissue engineered Constructs
- Each well of a 96 well plate was coated with 100 ⁇ l of 2% molecular biology grade agarose (Sigma). The plates were tilted to spread the agarose along the walls, and then inverted to shake out the excess agarose.
- To each well 5.5 million chondrocytes in 300 ⁇ l of culture medium were introduced.
- the cells formed non-attached constructs at the bottom of each well, and these constructs were maintained in the 96 well plates for 4 wks before being transferred to agarose coated 46 well plates.
- Constructs from both treatments increased in opacity over time. After 24 hrs, cells on agarose formed one cohesive nodule that was not attached to the substratum. Other than the single nodule, the agarose surface did not have any other attached cells or nodules. In contrast, the control cells readily attached to the bottom of the TCP wells and formed nodules that adhered to TCP and detached from the constructs as time progressed. Constructs cultured over agarose appeared smooth, flat, and hyaline-like in appearance. Disks 6-mm in diameter were punched out of the center of the constructs cultured over agarose for mechanical testing, and these are shown in Figure 1, rows 1 and 2.
- the constructs cultured on TCP became contorted with folds ( Figure 2).
- the constructs were not of uniform thickness throughout, and the thickness of the thinnest portion (the 6-mm punched out disks) is reported, since this was the mechanically tested region.
- the constructs formed over agarose were significantly thicker than those formed over TCP for these time points.
- the secondary antibody (mouse IgG, Vectastain ABC kit) was then applied, and color was developed using the Vectastain ABC reagent and DAB (Vector Laboratories ).
- DAB Vectastain ABC reagent and DAB (Vector Laboratories ).
- Total sulfated GAG was then quantified using the Blyscan Glycosaminoglycan Assay kit (Biocolor), based on 1 ,9-dimethylmethylene blue binding. After being hydrolyzed by 2 N NaOH for 20 min at 110 0 C, samples were assayed for total collagen content by a chloramine- T hydroxyproline assay.
- Biocolor Blyscan Glycosaminoglycan Assay kit
- Total DNA content was measured by Picogreen® Cell Proliferation Assay Kit (Molecular Probes).
- Total sulfated GAG was then quantified using the Blyscan Glycosaminoglycan Assay kit (Biocolor), based on 1,9- dimethylmethylene blue binding. After being hydrolyzed by 2 N NaOH for 20 min at 110 0 C, samples were assayed for total collagen content by a chloramine-T hydroxyproline assay.
- Constructs cultured over agarose gained mass over the culture period, and, at each time point, these constructs contained significantly larger mass than constructs cultured on TCP.
- the total cell number did not show significant changes during the culture period and ranged from 5.8 ⁇ 1.2 to 7.1 ⁇ 1.2 million per construct.
- the number of cells in these constructs was more, though not significantly, than the constructs cultured over TCP, which showed an increase in cell number from 4.5 ⁇ 1.2 to 6.3 ⁇ 1.4 million cells per construct over the culture period.
- the constructs formed over agarose contained significantly higher GAG and collagen per sample at each time point when compared to control (Figure 3).
- samples were evaluated with an automated indentation apparatus. Each specimen was attached to the sample holder by use of cyanoacrylate glue, and was submerged in saline solution. The specimen was positioned under the load shaft of the apparatus so that the sample surface test point was perpendicular to the indenter tip. The specimen was automatically loaded with a tare mass of 0.4 g (0.004 N), using a 1.67 mm- diameter rigid, flat-ended, porous indenter tip. Samples were allowed to reach tare creep equilibrium, which was defined as deformation ⁇ 10 ⁇ mm/s or a maximum creep time of 10 min. When tare equilibrium was reached, a step mass of 2.34 g (0.023 N) was applied.
- "Aggregate modulus” is a conventional measurement used in characterizing cartilage.
- the samples reached an HA of 53 ⁇ 9 kPa after 12 wks (See Table 1 below).
- the permeability and Poisson's ratio values were not significantly different across the two treatments.
- constructs cultured on TCP reached 14% of the stiffness of calf articular cartilage, whereas constructs on agarose reached 31%.
- constructs cultured over agarose increased their stiffness to almost 40% of the stiffness of native tissue.
- Extended culture periods, bioactive agents, or mechanical stimuli may aid this tissue to further progress down this pathway towards native tissue-like functionality.
- Control specimens were placed into an opened pressure chamber, while pressure specimens were placed into a pressure chamber (Parr Instrument Company), filled with water, and sealed underwater without any bubbles inside.
- the pressure chamber is a 1.2 L stainless-steel vessel capable of withstanding pressures upwards of 13 MPa ( Figure 5, A). It is connected to a water-driven piston (PHD Inc.) ( Figure 5, B) via a stainless-steel !4" hose (Dunlop) rated for pressures up to 40 MPa.
- the piston is connected to an Instron 8871 ( Figure 5, C), controlled using the Instron WaveMaker software. For 5 consecutive days a week, the specimens were pressurized to 10 MPa at 1 Hz using a sinusoidal waveform for 4 hrs.
- the pressure chamber was disassembled, and the pouches were sterilized with 70% ethanol.
- the pouches were opened with autoclaved instruments and the samples were then returned to orbitally shaken culture dishes.
- the pressure set-up assembled in this study applied intermittent hydrostatic pressure at 10 MPa, 1 Hz, 4 hrs a day consistently over an 8-week period. Articular chondrocyte constructs subjected to this loading regimen were shown to withstand the repeated mechanical stimulus.
- mice anti-collagen type I antibody (Accurate Chemicals) at 1 :1500 dilution in PBS or mouse anti-collagen type II antibody (Chondrex) at 1 :1000 dilution on PBS.
- the secondary antibody (antimouse IgG, Vectastain ABC kit) was then applied, and color was developed using the Vectastain ABC reagent and DAB (Vector Laboratories).
- Slides stained with mouse IgG l/2a/2b (Accurate Chemicals) served as negative controls. The gross appearance of the 3-D culture is shown in Figure 6. After 4 wks of culture, the pressurized samples reached thicknesses of 2.01 ⁇ 0.04 mm.
- Total DNA content was measured by Picogreen® Cell Proliferation Assay Kit (Molecular Probes).
- Total sulfated GAG was then quantified using the Blyscan Glycosaminoglycan Assay kit (Biocolor), based on 1,9- dimethylmethylene blue binding. After being hydrolyzed by 2 N NaOH for 20 min at 110 0 C, samples were assayed for total collagen content by a chloramine-T hydroxyproline assay.
- pressurized constructs reached a wet weight (WW) of 87.5 ⁇ 7.5 mg, and the wet weight remained steady, reaching 92.7 ⁇ 9.0 mg at 8 wks.
- WW wet weight
- Control sample WW was 92.3 ⁇ 5.6 mg at 4 wks and 83.9 ⁇ 11.7 mg at 8 wks. This decrease was not statistically significant.
- Total GAG per construct significantly decreased in the control samples, while the pressurized samples showed an insignificant decrease (Figure 8).
- samples were evaluated with an automated indentation apparatus. Each specimen was attached to the sample holder by use of cyanoacrylate glue, and was submerged in saline solution. The specimen was positioned under the load shaft of the apparatus so that the sample surface test point was perpendicular to the indenter tip. The specimen was automatically loaded with a tare mass of 0.4 g (0.004 N), using a 1.67 mm- diameter rigid, flat-ended, porous indenter tip. Samples were allowed to reach tare creep equilibrium, which was defined as deformation ⁇ 10 "6 mm/s or a maximum creep time of 10 min. When tare equilibrium was reached, a step mass of 2.34 g (0.023 N) was applied.
- the permeability of the samples also remained constant throughout the culture period.
- the Poisson's ratio values of constructs ranged from 0.006 to 0.015 across treatments and were not significantly different over culture time.
- Example 10-11 Analysis of Tissue engineered Constructs formed on Pressed Hydrogel Coated Surfaces
- Example 10 Formation and Analysis of the Shaped Constructs Cell suspensions were seeded on the cooled, pressed hydrogel coated surfaces. See
- Figure 10 Figure 10, Figure 11, and Figure 12.
- 100% articular chondrocytes and 100% meniscal f ⁇ brochondrocytes were seeded on the hydrogel coated surfaces. Co-cultures of the two were also seeded comprising: 75% articular chondrocytes and 25% meniscal f ⁇ brochondrocytes, 50% articular chondrocytes and 50% meniscal f ⁇ brochondrocytes, and 25% articular chondrocytes and 75% meniscal f ⁇ brochondrocytes.
- Figure 13 is an image of the developing shaped construct. See also Figure 22.
- the tensile modulus of the developing constructs were analyzed using known techniques.
- the tensile modulus appears to increase with increasing fibrochondrocyte composition (See Figure 17).
- the ultimate tensile strength of the developing constructs were analyzed using know techniques. The ultimate tensile strength of the constructs also appears to increase with increasing fibrochondrocyte composition. (See Figure 16).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78985106P | 2006-04-05 | 2006-04-05 | |
US78985506P | 2006-04-05 | 2006-04-05 | |
US78985306P | 2006-04-05 | 2006-04-05 | |
PCT/US2007/066089 WO2007115336A2 (fr) | 2004-07-09 | 2007-04-05 | Approche basée sur la forme pour ingéniérie tissulaire sans échafaudage |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2007312A2 true EP2007312A2 (fr) | 2008-12-31 |
EP2007312A4 EP2007312A4 (fr) | 2012-08-22 |
Family
ID=38564326
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07760211A Withdrawn EP2007881A4 (fr) | 2006-04-05 | 2007-04-05 | Ingéniérie tissulaire utilisant des cellules souches embryonnaires humaines |
EP07760205A Withdrawn EP2007875A4 (fr) | 2006-04-05 | 2007-04-05 | Cellules dérivées du derme pour des applications de génie histologique |
EP20070760209 Withdrawn EP2007312A4 (fr) | 2006-04-05 | 2007-04-05 | Approche basée sur la forme pour ingéniérie tissulaire sans échafaudage |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07760211A Withdrawn EP2007881A4 (fr) | 2006-04-05 | 2007-04-05 | Ingéniérie tissulaire utilisant des cellules souches embryonnaires humaines |
EP07760205A Withdrawn EP2007875A4 (fr) | 2006-04-05 | 2007-04-05 | Cellules dérivées du derme pour des applications de génie histologique |
Country Status (4)
Country | Link |
---|---|
EP (3) | EP2007881A4 (fr) |
AU (3) | AU2007254048A1 (fr) |
CA (3) | CA2648648A1 (fr) |
WO (3) | WO2007136936A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005058207A1 (fr) | 2003-12-11 | 2005-06-30 | Isto Technologies, Inc. | Systeme chondral particulaire |
WO2005081970A2 (fr) | 2004-02-24 | 2005-09-09 | The Curators Of The University Of Missouri | Agregats cellulaires d'auto-assemblage et procedes de fabrication de tissu genetiquement modifies utilisant de tels agregats |
US20110212894A1 (en) * | 2004-07-09 | 2011-09-01 | Athanasiou Kyriacos A | Decellularization method for scaffoldless tissue engineered articular cartilage or native cartilage tissue |
WO2010022074A1 (fr) * | 2008-08-18 | 2010-02-25 | William Marsh Rice University | Procédé de décellularisation pour cartilage articulaire modifié de tissu sans échafaudage ou pour tissu de cartilage natif |
WO2009111390A1 (fr) * | 2008-03-03 | 2009-09-11 | William Marsh Rice University | Procédés de fabrication d'un cartilage amélioré d'ingénierie tissulaire |
WO2007025290A2 (fr) | 2005-08-26 | 2007-03-01 | Isto Technologies, Inc. | Implants et procedes pour la reparation, le remplacement et le traitement de maladies articulaires |
US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US20090012629A1 (en) | 2007-04-12 | 2009-01-08 | Isto Technologies, Inc. | Compositions and methods for tissue repair |
US9303245B2 (en) * | 2008-06-20 | 2016-04-05 | Universiteit Maastricht | Self-assembling tissue modules |
KR20170020942A (ko) | 2008-06-24 | 2017-02-24 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | 자가-조립가능 다세포체 및 이들을 이용하여 3차원 생물학적 구조체를 생산하는 방법 |
CA2768376C (fr) * | 2009-07-16 | 2023-01-03 | Biotime, Inc. | Procedes et compositions pour chondrogenese in vitro et in vivo |
DK2629975T3 (da) | 2010-10-21 | 2022-05-09 | Organovo Inc | Anordninger til fremstilling af væv |
WO2013010045A1 (fr) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Nouveaux procédés et formulations pour thérapie cellulaire orthopédique |
US9499779B2 (en) | 2012-04-20 | 2016-11-22 | Organovo, Inc. | Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking |
US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
US9442105B2 (en) | 2013-03-15 | 2016-09-13 | Organovo, Inc. | Engineered liver tissues, arrays thereof, and methods of making the same |
CA2919734C (fr) | 2013-07-31 | 2023-04-25 | Organovo, Inc. | Dispositifs, systemes et procedes automatises pour la fabrication de tissus |
CA3177480A1 (fr) | 2014-04-04 | 2015-10-08 | Organovo, Inc. | Tissu mammaire tridimensionnel artificiel, tissu adipeux, et modele de maladies tumorales |
US9670443B2 (en) * | 2014-06-25 | 2017-06-06 | University Of Leeds | Tissue engineered constructs |
KR20170064547A (ko) | 2014-10-06 | 2017-06-09 | 오가노보, 인크. | 조작된 신장 조직, 이의 어레이, 및 이를 제조하는 방법 |
WO2016073782A1 (fr) | 2014-11-05 | 2016-05-12 | Organovo, Inc. | Tissus cutanés tridimensionnels manipulés, ensembles correspondants et leurs procédés de production |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020106625A1 (en) * | 2002-02-07 | 2002-08-08 | Hung Clark T. | Bioreactor for generating functional cartilaginous tissue |
WO2006017176A2 (fr) * | 2004-07-09 | 2006-02-16 | William Marsh Rice University | Constructions sans echafaudage pour genie tissulaire de cartilage articulaire |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE258810T1 (de) * | 1995-11-09 | 2004-02-15 | Univ Massachusetts | Wiederherstellung der gewebeoberfläche mit zusammensetzungen aus hydrogel-zellen |
EP1159404A2 (fr) * | 1999-03-02 | 2001-12-05 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Lignees cellulaires embryonnaires ou de type souche produites par transplantation nucleaire d'especes croisees |
IL154159A0 (en) * | 2000-08-01 | 2003-07-31 | Yissum Res Dev Co | Directed differentiation of ebryonic cells |
AU2002258477A1 (en) * | 2001-03-08 | 2002-09-24 | Advanced Cell Technology, Inc. | Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture |
KR100973453B1 (ko) * | 2001-12-07 | 2010-08-02 | 제론 코포레이션 | 인간 배아 줄기 세포에서 유래되는 연골세포 전구체 |
EP1490477A4 (fr) * | 2002-04-02 | 2006-08-30 | Univ Rice William M | Cellules redifferenciees utilisees pour reparer les defauts du cartilage |
US20040082063A1 (en) * | 2002-10-18 | 2004-04-29 | Reliance Life Sciences Pvt. Ltd. | Tissue-like organization of cells and macroscopic tissue-like constructs, generated by macromass culture of cells, and the method of macromass culture |
-
2007
- 2007-04-05 WO PCT/US2007/066085 patent/WO2007136936A2/fr active Application Filing
- 2007-04-05 CA CA002648648A patent/CA2648648A1/fr not_active Abandoned
- 2007-04-05 AU AU2007254048A patent/AU2007254048A1/en not_active Abandoned
- 2007-04-05 WO PCT/US2007/066089 patent/WO2007115336A2/fr active Application Filing
- 2007-04-05 CA CA002648327A patent/CA2648327A1/fr not_active Abandoned
- 2007-04-05 EP EP07760211A patent/EP2007881A4/fr not_active Withdrawn
- 2007-04-05 EP EP07760205A patent/EP2007875A4/fr not_active Withdrawn
- 2007-04-05 AU AU2007234365A patent/AU2007234365A1/en not_active Abandoned
- 2007-04-05 WO PCT/US2007/066092 patent/WO2007115337A2/fr active Application Filing
- 2007-04-05 CA CA002648332A patent/CA2648332A1/fr not_active Abandoned
- 2007-04-05 AU AU2007234366A patent/AU2007234366A1/en not_active Abandoned
- 2007-04-05 EP EP20070760209 patent/EP2007312A4/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020106625A1 (en) * | 2002-02-07 | 2002-08-08 | Hung Clark T. | Bioreactor for generating functional cartilaginous tissue |
WO2006017176A2 (fr) * | 2004-07-09 | 2006-02-16 | William Marsh Rice University | Constructions sans echafaudage pour genie tissulaire de cartilage articulaire |
Non-Patent Citations (2)
Title |
---|
C R LEE ET AL: "Modulation of the Contractile and Biosynthetic Activity of Chondroxytes Seeded in Collagen-Glycosaminoglycan Matrices", TISSUE ENGINEERING, vol. 9, no. 1, 1 January 2003 (2003-01-01) , pages 27-36, XP55032370, * |
See also references of WO2007115336A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2007254048A1 (en) | 2007-11-29 |
WO2007136936A2 (fr) | 2007-11-29 |
WO2007115337A8 (fr) | 2007-12-13 |
CA2648648A1 (fr) | 2007-11-29 |
AU2007234365A1 (en) | 2007-10-11 |
EP2007881A2 (fr) | 2008-12-31 |
WO2007115337A2 (fr) | 2007-10-11 |
WO2007115336A3 (fr) | 2008-05-22 |
EP2007875A2 (fr) | 2008-12-31 |
EP2007875A4 (fr) | 2009-12-16 |
CA2648332A1 (fr) | 2007-10-11 |
EP2007312A4 (fr) | 2012-08-22 |
WO2007136936A3 (fr) | 2008-10-23 |
AU2007234366A1 (en) | 2007-10-11 |
WO2007115336A2 (fr) | 2007-10-11 |
EP2007881A4 (fr) | 2009-07-08 |
CA2648327A1 (fr) | 2007-10-11 |
WO2007115337A3 (fr) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090142307A1 (en) | Shape-Based Approach for Scaffoldless Tissue Engineering | |
EP2007312A2 (fr) | Approche basée sur la forme pour ingéniérie tissulaire sans échafaudage | |
Flanagan et al. | A collagen-glycosaminoglycan co-culture model for heart valve tissue engineering applications | |
Dunkelman et al. | Cartilage production by rabbit articular chondrocytes on polyglycolic acid scaffolds in a closed bioreactor system | |
US6652583B2 (en) | Cardiac valve replacement | |
US9370606B2 (en) | Scaffold-free self-organized 3D synthetic tissue | |
Ibsirlioglu et al. | Decellularized biological scaffold and stem cells from autologous human adipose tissue for cartilage tissue engineering | |
US7476257B2 (en) | Methods to engineer stratified cartilage tissue | |
US20200121463A1 (en) | Scaffold-free self-organizing 3d synthetic tissue and artificial bone complex for bone/cartilage regeneration | |
Wu et al. | The use of cocultured mesenchymal stem cells with tendon-derived stem cells as a better cell source for tendon repair | |
EP2780048B1 (fr) | Petit tissu à base de dextrane contenant un lysat à plasma riche en plaquettes pour la réparation des cartilages | |
Kinner et al. | Expression of smooth muscle actin in osteoblasts in human bone | |
JP2024038337A (ja) | 神経再生、骨形成、及び血管新生を刺激するためのヒドロゲル | |
CN113677700A (zh) | 细胞结构体及细胞结构体的制造方法 | |
JP7058607B2 (ja) | カスタマイズされた骨-インプラントハイブリッド移植片 | |
US11786636B2 (en) | Methods for complex tissue engineering | |
US20090136559A1 (en) | Chondrocyte Differentiation from Human Embryonic Stem Cells and Their Use in Tissue Engineering | |
EP2949747B1 (fr) | Création de tissu artificiel tridimensionnel à partir de cellules dérivées de cellules souches pluripotentes et traitement de régénération ostéochondrale utilisant ledit tissu artificiel | |
US8637065B2 (en) | Dermis-derived cells for tissue engineering applications | |
JP2022550911A (ja) | 軟骨形成ヒト間葉系幹細胞(msc)シート | |
Pleumeekers | Face it: Cell-based therapy for the reconstruction of cartilage defects in the head and neck area. | |
Li et al. | Construction of Integral Decellularized Cartilage Using a Novel Hydrostatic Pressure Bioreactor | |
Hoben | Self assembly of fibrochondrocytes and human embryonic stem cells for tissue engineering of fibrocartilage | |
Russell | Re-engineering brain tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081104 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120719 |
|
17Q | First examination report despatched |
Effective date: 20130506 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150807 |